Date:12/17/2010

-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

'/>"/>

SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
2. Mylan Announces the Conversion of its Preferred Stock into Common Stock
3. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
4. Third Circuit Denies Mylan Motion for Interim Injunction
5. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
8. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
9. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
10. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
11. Mylan Launches Generic Version of Wellbutrin XL® Tablets